127589-93-9

Usage

Uses

Used in Pharmaceutical Industry:
1,1-DIMETHYLETHYL-(R,S)-4-FORMYL-2,2-DIMETHYL-3-OXAZOLIDINECARBOXYLATE is used as a synthetic intermediate for the preparation of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
1,1-DIMETHYLETHYL-(R,S)-4-FORMYL-2,2-DIMETHYL-3-OXAZOLIDINECARBOXYLATE is used as a reagent in the synthesis of unsaturated carboxylic esters. Its formyl group can be selectively reduced or oxidized, providing a range of functional groups that can be further elaborated upon in organic synthesis.
Used in Material Science:
1,1-DIMETHYLETHYL-(R,S)-4-FORMYL-2,2-DIMETHYL-3-OXAZOLIDINECARBOXYLATE can be used as a monomer or building block in the development of new polymers and materials with specific properties. Its oxazolidine ring and formyl group can be incorporated into polymer backbones, leading to materials with unique characteristics.
Used in Research and Development:
1,1-DIMETHYLETHYL-(R,S)-4-FORMYL-2,2-DIMETHYL-3-OXAZOLIDINECARBOXYLATE is used as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it an interesting target for the development of new synthetic methods and applications in various fields.

Upstream product

• 157604-46-1 3-tert-butyl 4-methyl 2,2-dimethyl-1,3-oxazolidine-3,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 108149-63-9 4-hydroxymethyl-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 69942-12-7 N-tert-butoxycarbonylserine methyl ester 

Downstream Products

• 129483-74-5 4-(1-Methoxycarbonylmethyl-2-phenyl-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 129483-67-6 (E)-4-tert-Butoxycarbonylamino-5-(3,3,3-trifluoro-2-methoxy-2-phenyl-propionyloxy)-pent-2-enoic acid methyl ester 
• 129483-74-5 4-(1-Methoxycarbonylmethyl-2-phenyl-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 129483-67-6 (E)-4-tert-Butoxycarbonylamino-5-(3,3,3-trifluoro-2-methoxy-2-phenyl-propionyloxy)-pent-2-enoic acid methyl ester 
• 272772-31-3 (+/-)-3-(N-tert-butoxycarbonyl)-2,2-dimethyl-4-[(4-tolyl)hydroxymethyl]-1,3-oxazolidine 
• 115378-31-9 tert-butyl (4R)-2,2-dimethyl-4-vinyloxazolidine-3-carboxylate 
• 133625-87-3 tert-butyl (4S)-2,2-dimethyl-4-vinyl-1,3-oxazolidine-3-carboxylate 

Relevant academic research and scientific papers

PYRROLE COMPOUNDS

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Ugi four-component reaction of alcohols: Stoichiometric and catalytic oxidation/MCR sequences

A new, simple, and efficient procedure for the one-pot Ugi four-component reaction of alcohols instead of aldehydes is described. Using a stoichiometric amount of IBX or only 1-2% of sodium 2-iodobenzenesulfonate in the presence of Oxone, a wide range of primary alcohols were oxidized to the aldehyde that were directly engaged in the Ugi four-component reaction to afford α-acetamidoamides in good to excellent yields.

Enantioselective synthesis of Garner's aldehyde by asymmetric hydroformylation

Both enantiomers of Garner's aldehyde (3) are prepared from the same alkene 4 by catalytic asymmetric hydroformylation.

SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR

An object of the invention is to provide a novel sphingosine compound with an inhibitory activity against sphingomyelinase, and a method for producing the sphingosine compound. The novel sphingosine compound or a salt thereof according to the invention is represented by Formula (1): wherein one of R1 and R2 is hydrogen, and the other is a group represented by Formula (G): wherein n is 0 or 1; and R3 is hydrogen, C1-23 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C1-6 alkoxy, C3-8 cycloalkyloxy, phenyl, or furil.

A solid-phase approach to DDB derivatives

Since the discovery of 2,2′-dimethoxycarbonyl-4,4-dimethoxy-5,6, 5′,6′-biomethylenedioxy-biphenyl (DDB) as a potent anti-HBV agent, we have studied the structure-activity relationships of 4,4′-dimethoxy-5, 6,5′,6′-dimethenedioxy-2-alkyloxycarbonyl-2′-(4-substituted benzyl piperazin-1-yl)carbonyl-biphenyl as anti-HBV agents. Therefore, it is rational to extend this study to the 3,3′-disustituted-4,4′- dimethoxy-5,6,5′,6′-dimethenedioxy-2-alkyloxycarbonyl-2′- Serine derivatives. Thus, in an attempt to develop an efficient method for the preparation of a large number of DDB derivatives, the reaction between a DDB acid chloride and serine derivatives on solid support was studied. The structure of resulted compounds was confirmed by LC-MS and 1H NMR analysis. Compounds 2a, 2d, 2f, 2j showed in vitro anti-HBV activity without significant toxicity up to 100 μM.